Celon PharmaWAR:CLN -0.60%49 Days Payable is 223.99 as of Mar. 2026, which is 132% above its 10-year median of 96.71. GuruFocus rates WAR:CLN with a GF Score™ of 49/100 and a GF Value™ of zł22.86 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 921 Drug Manufacturers companies, Celon Pharma ranks better than 74.48% on this metric.
The historical rank and industry rank for Celon Pharma's Days Payable or its related term are showing as below:
WAR:CLN'
s Days Payable Range Over the Past 10 Years
Min: 61.85 Med: 96.71 Max: 148.36
Current: 148.36
During the past 11 years, Celon Pharma's highest Days Payable was 148.36. The lowest was 61.85. And the median was 96.71.
WAR:CLN's Days Payable is ranked better than 74.48% of 921
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs WAR:CLN: 148.36
Celon Pharma's Days Payable
increased
from Mar. 2025 (91.04) to Mar. 2026 (223.99).
It may suggest that Celon Pharmadelayed paying its suppliers.
Celon Pharma Days Payable Related Terms
Celon Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Celon Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CLN vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Celon Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Celon Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma (WAR:CLN) has a Days Payable of 223.99 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Celon Pharma and its competitors. This is 132% above median its historical median of 96.71. Over the past decade, Celon Pharma's Days Payable has ranged from 61.85 to 148.36. According to the industry distribution chart, Celon Pharma ranks #235 out of 921 companies in the Drug Manufacturers industry, placing it in the top 25.5%.
Is Celon Pharma's Days Payable too high?
Celon Pharma's current Days Payable of 223.99 is 132% above median its 10-year median of 96.71. Over the past 10 years, this metric has ranged from a low of 61.85 to a high of 148.36. The Drug Manufacturers industry median Days Payable is 90.69. Celon Pharma's value of 223.99 is 147% above this industry median. Based on the distribution chart, Celon Pharma ranks #235 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Celon Pharma has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #235 out of 921 companies for Days Payable. This puts Celon Pharma in the upper half of its industry. The industry median Days Payable is 90.69. Celon Pharma's value of 223.99 is 147% above this benchmark. Historically, Celon Pharma's own Days Payable has ranged from 61.85 to 148.36 over the past decade. While the company's 10-year median is 96.71 vs. the industry median of 90.69, Celon Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current Days Payable of 223.99 is 147% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current Days Payable is 223.99, which is 132% above median its own 10-year median of 96.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł22.86, compared to a current price of zł19.72 — trading 13.7% below its estimated fair value. The current Days Payable is 223.99, which is 132% above median its 10-year median of 96.71 and 147% above the Drug Manufacturers industry median of 90.69. Celon Pharma's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Days Payable is 223.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (WAR:CLN) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł19.72 is trading 13.7% below its estimated GF Value™ of zł22.86.
GuruFocus considers Celon Pharma to be Modestly Undervalued.
Key valuation signals for WAR:CLN:
Days Payable: 223.99 (132% above median its 10-year median of 96.71)
GF Value™: zł22.86 vs. price of zł19.72 (13.7% below fair value)
Industry Position: 147% above the Drug Manufacturers median (#235 of 921)
No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
49GF Score
Get the complete analysis for WAR:CLN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CLN has been successfully added to your 
